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Abstract
Background: Osteoarthritis (OA) is a degenerative joint disease which affects the entire joint structure, including
the synovial membrane. Disease progression was shown to involve inflammatory changes mediated by proteinase-
activated receptor (PAR)-2. Previous studies demonstrated that PAR-2 messenger (m)RNA and protein levels
increased in OA synovial cells, suggesting that PAR-2 is a potential therapeutic target of the disease.
Methods: We designed a PAR-2-inhibiting peptide (PAR2-IP) by changing an isoleucine residue in the PAR-2-
activating peptide (PAR2-AP), SLIGKV, to alanine, generating the SLAGKV peptide. We used it to test PAR-2-
mediated inflammatory responses, including the expressions of cyclooxygenase (COX)-2 and matrix
metalloproteinase (MMP)-1 and activation of nuclear factor (NF)-B in human synovial cells. As a control,
expressions of COX-2 and MMP-1 were induced by trypsin at both the mRNA and protein levels.
Results: The PAR2-AP increased the expression of COX-2 more dramatically than that of MMP-1. When we treated
cells with the designed PAR2-IP, the trypsin-induced COX-2 level was completely inhibited at a moderate
concentration of the PAR2-IP. With further examination of trypsin-induced NF-B activation, we observed sufficient
inhibitory effects of the PAR2-IP in synoviosarcoma cells and primary synovial cells from OA patients.
Conclusions: Our study suggests that the PAR2-IP inhibits trypsin-induced NF-B activation, resulting in a
reduction in inflammatory COX-2 expression in synovial cells. Application of PAR2-IP is suggested as a potential
therapeutic strategy for OA.
Background
Osteoarthritis (OA) is a degenerative joint disease in
which degradation of the cartilage structure is found. A
recent investigation demonstrated the significant involve-
ment of inflammatory processes in OA pathogenesis [1].
Induction of inflammatory factors, such as interleukin
(IL)-1b, by hormone disruption and/or other factors was
shown to contribute to the disease progression [2,3].
Studies on patients and a mouse model demonstrated a
key role of proteinase-activated receptor (PAR)-2 in med-
iating arthritic inflammation [4-7]. PARs belong to the
G-protein coupled receptor family that is activated by
serine protease-mediated cleavage of the N-terminus of
the receptors [8,9]. Mounting evidence indicated that
trypsin cleaves PAR-2 at R
34↓S
35LIGKV (in human) to
expose a hexameric-tethered peptide that binds to con-
served regions in the extracellular second loop of the
receptor to initiate signaling [10]. The synthetic peptide
(PAR2-AP) corresponding to the tethered ligand domain,
SLIGKV, mimics the effects of trypsin in cell lines
that naturally express PAR-2. Studies also showed that
secreted proinflammatory cytokines up-regulate expres-
sion of PAR-2, stimulating more secretion of proinflam-
matory cytokines and metalloproteinases to enhance
inflammatory responses [7,11,12]. When activated, PAR-
2 is coupled to nuclear factor (NF)-B activation in cells
[13].
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regulates expressions of numerous genes, including
cyclooxygenase (COX)-2 and matrix metalloproteinases
(MMPs) [14,15]. NF-B is constitutively present in cells as
a heterodimer, consisting of a p50 DNA-binding subunit
and a p65 transactivating subunit. NF-B is normally
found in the cytoplasm in an inactivated state by binding
to an inhibitor, such as IBa.N F - B activation in
response to proinflammatory stimuli involves phosphory-
lation of IBa, leading to its proteasomal degradation,
which enables NF-B transcription factors to be translo-
cated to the nucleus [16,17]. Optimal induction of NF-B
target genes also requires phosphorylation of NF-B pro-
teins, such as p65, in response to distinct stimuli [14].
COX-2 is the key enzyme regulating the production of
prostaglandin E2 (PGE2), a central mediator of inflam-
mation. In articular chondrocytes, proinflammatory cyto-
k i n e ss u c ha sI L - 1 b and tumor necrosis factor (TNF)-a
synergistically induce COX-2 [18]. Recently, the expres-
sion of COX-2 was shown to be induced by the activation
of PAR-2 through bacterial infection, or the treatment of
either trypsin or PAR2-AP, and mediated inflammation
in some cell types [19,20]. Inhibition of COX-2 antago-
nized trypsin-induced PAR-2-dependent itching in an
animal model [21].
MMPs mediate cartilage degradation by specifically
cleaving matrix proteins [22]. Studies showed that IL-1b
also induces expressions of MMPs [23,24]. There is exten-
sive evidence that among MMPs, MMP-1 (collagenase 1),
MMP-3 (stromelysin 1), and MMP-13 (collagenase 3) are
particularly involved in the OA process [25,26]. Recent
study indicated that activation of PAR-2 with the activat-
ing peptide induced a significant up-regulation of MMP-1
in bone osteoblasts [27].
Our previous study showed that PAR-2 is expressed in
OA synovial cells without stimulation [12]. Treatment
with IL-1b increased PAR-2 expression, which can be
repressed by transforming growth factor (TGF)-b through
multiple pathways in those cells. To further investigate
how PAR-2 can be a potential therapeutic target of
osteoarthritis (OA), we designed a PAR-2-inhibiting pep-
tide (PAR2-IP) by replacing an isoleucine residue in the
PAR2-AP with alanine, generating the SLAGKV peptide.
When synovial cells were treated with the PAR2-IP, tryp-
sin-induced NF-B activation was inhibited, and the
COX-2 level was reduced. Herein, we tested an effective
PAR-2-inhibiting peptide, in the hopes of providing a
potential therapeutic strategy for OA.
Methods
Cell culture
Human synovial cells and chondrocytes were isolated
from patients undergoing joint replacement surgery [3,12].
Tissues were cut into pieces (2
~3m m
3). Chondrocytes
and synovial cells were released from articular tissues by
sequential incubation with 0.1% hyaluronidase (Sigma, St.
Louis, Mo, USA) for 15 min, 0.5% proteinase for 30 min,
and 0.2% collagenase (Sigma) for 12 h at 37°C in Dulbec-
cok’s modified Eagle’sm e d i u m( D M E M )( G i b c oB R L ,
Grand Island, NY, USA). After isolation, chondrocytes and
synovial cells were individually resuspended in DMEM
containing 10% fetal bovine serum (FBS), a 1% penicillin-
streptomycin solution, a 1% amphotericin B solution, and
1% L-glutamine, and then incubated at 37°C with 5% CO2.
The media were changed every 3
~4d a y s .
A human synoviosarcoma fibroblast-like synovium cell
line, SW982, was cultured in 60-mm diameter dishes in
Leibovitz’s L-15 medium containing 15% FBS, a 1%
penicillin-streptomycin solution, a 1% amphotericin B
solution, and 1% L-glutamine at 37°C without CO2.T h e
medium was replaced every 1
~2 days.
Cell treatments
When cells reached 80% confluence, they were treated
with various concentrations of stimulants for a certain
time period in serum-free medium for the dose-dependent
analysis, or they were treated with a specific concentration
of stimulants for various time periods for the time-course
analysis. Trypsin was purchased from Gibco. IL-1b was
from R&D Systems, Inc. PAR2-AP and PAR2-IP were
from Genemed Synthsis, Inc. PAR2-IP was designed by
replacing the isoleucine residue in PAR2-AP (SLIGKV)
with alanine, generating the SLAGKV peptide.
RNA extraction and polymerase chain reaction (PCR)
To evaluate the messenger (m)RNA levels of COX-2
and MMP-1, total RNA was extracted from SW982 cells
using the Trizol reagent (Invitrogen). Reverse transcrip-
tion was performed using the oligo dT18 primer and
MMLV-derived reverse transcriptase as described else-
where [12].
PCR primers for amplification of specific complemen-
tary (c)DNAs were synthesized according to the following
oligonucleotide sequences: COX-2 sense, 5’-AAACCT-
CAGCTCAGGACTGC-3’ and antisense, 5’-GGCAC-
TAGCCTCTTTGCATC-3’; MMP-1 sense, 5’-GTCAGGG
GAGATCATCGG-3’ and antisense, 5’-GCCCAGTACT-
TATTCCCT-3’; and GAPDH sense, 5’-CAAGGCTGAGA
ACGGGAAGC-3’ and antisense, 5’-AGGGGGCAGA-
GATGATGACC-3’. The PCR was carried out with 2 μlo f
template cDNA and 23 μl of PCR buffer containing each
primer (0.2 μM), dNTP (2.5 mM), and Taq DNA polymer-
ase (1.25 units) (Takara Bio Inc, Japan). In each PCR, 30
cycles of 30 s at 94°C, 30 s at a primer-specific annealing
temperature, and 30 s at 72°C were performed in a Crea-
con Technology PCR System (Southern Africa). The RNA
level of GAPDH was determined in every sample as an
internal control. After amplification, the products were
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with ethidium bromide, and illuminated with a UV lamp.
Cell lysate preparation
Whole-cell lysates were obtained from SW982 and pri-
mary synovial cells. Cells were washed with PBS, and then
lysed in 50 μl of golden lysis buffer containing 20 mM
T r i s / H C l( p H7 . 9 ) ,1 3 7m MN a C l ,5m ME D T A ,1m M
EGTA, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM
sodium pyrophosphate, 0.1 mM b-glycerophosphate,
2 mM phenylmethylsulfo-nylfluoride (PMSF), 0.8 nM
aprotinin,10 nM leupeptin, and 5 mM dithiothreitol. Pro-
tein concentrations were determined using a Bio-rad assay.
Western blotting
Equal amounts of whole-cell lysates were analyzed on 10%
sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE). After electrophoresis, proteins were trans-
ferred to polyvinylidene difluoride (PVDF)-nylon mem-
branes. The membranes were blocked with TBST
containing 3% bovine serum albumin (BSA) at room tem-
perature for 1 h, and then incubated with primary antibo-
dies against COX-2 (Millipore) at 1:500, MMP-1
(Chemicon, Inc) at 1:1000, IBa (Santa Cruz Biotechnol-
ogy) at 1:1000, phosphorylated (p)-p65 (Cell signaling
technology) at 1:1000, and GAPDH (Zymed) at 1:1000 in
TBST overnight at 4°C. After being washed with TBST
three times, the membranes were incubated with second-
ary antibodies at 1:10,000 in TBST at room temperature
for 1 h. After another three washes, membranes were
visualized using an enhanced chemiluminescence detec-
tion system (GE Healthcare).
Statistical analysis
Densities of bands on the gels were quantified by Image J
(NIH, USA). Results were normalized to the amount of
GAPDH. The mean and standard deviation were used to
evaluate COX-2 and MMP-1 expression levels. Student’s
t-test was used for the comparison. The effects of stimu-
lation by trypsin, cytokines, and PAR2-AP on COX-2 and
MMP-1 expression levels were analyzed as changes rela-
tive to an unstimulated baseline. These analyses were
performed individually at least three times. Statistical sig-
nificance was set to p < 0.05.
Results
Trypsin induced COX-2 and MMP-1 expressions
Trypsin cleaves PAR-2 and activates inflammatory
responses, but it is not clear how COX-2 and MMP-1
expressions are involved in this process in OA patient’s
cartilage. Therefore, we analyzed trypsin-induced COX-
2 and MMP-1 expressions in human primary chondro-
cytes and synovial cells isolated from patients under-
going joint replacement surgery. Trypsin at 30 nM was
able to increase COX-2 and MMP-1 protein levels
within 3 h in both cell types; however, the effect was
more obvious in synovial cells (Figure 1A, B). This is
consistent with higher PAR-2 expression in synovial
cells than in chondrocytes reported by a previous study
[12]. A further experiment using different concentra-
tions of trypsin demonstrated its dose-dependent effect
Figure 1 Induction of cyclooxidase-2 (COX-2) and matrix
metalloproteinase-1 (MMP-1) expression by trypsin in human
primary cells. Human primary cells were cultured as described in
Materials and Methods. COX-2 and MMP-1 expression levels after
trypsin treatment were analyzed by western blotting. Chondrocytes
(A) and synovial cells (B) were treated with 30 nM trypsin in serum-
free DMEM for different time periods as indicated. (C) Primary
synovial cells were treated with various concentrations of trpsin for
8 hours.
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(Figure 1C).
We then used the human synoviosarcoma SW982 cell
line as a model to examine trypsin-induced COX-2 and
MMP1 expressions. Similarly we observed an increased
COX-2 protein level by 30 nM trypsin within 3 h of
incubation in this cell line (Figure 2A). We found that
both the mRNA (Figure 2B) and protein (Figure 2C)
levels of COX-2 and MMP-1 increased with trypsin
treatment, suggesting that trypsin indeed induced the
expressions of these two proteins. Dose-dependent
effects of trypsin also suggested a close relationship
between the trypsin substrate, PAR-2, and the inflam-
matory genes, COX-2 and MMP-1.
PAR2-AP stimulated COX-2 and MMP-1 expressions in
synovial cells
In chondrocytes, PAR-2 activation by the activating pep-
tide (PAR2-AP), SLIGKV, significantly induced COX-2
and MMP-1 expressions [4]. To test whether the PAR2-
AP produces the same effect in synovial cells, we treated
SW982 cells with this PAR2-AP at different concentra-
tions for 24 h, and then analyzed COX-2 and MMP-1 pro-
tein levels. As a control, IL-1b, which was shown to
upregulate PAR-2 expression, increased both COX-2 and
MMP-1 levels in cells, suggesting a close correlation
between PAR-2 and these two inflammatory proteins
(Figure 3A). The PAR2-AP at ≥ 50 μM significantly
increased the COX-2 level, but had less effect on MMP-1.
Figure 2 Induction of cyclooxidase-2 (COX-2) and matrix metalloproteinase-1 (MMP-1) expression by trypsin in human
synoviosarcoma cells. Human synoviosarcoma SW982 cells were treated with trypsin in serum-free L15 medium. COX-2, MMP-1 and GAPDH
expressions were assayed by western blotting and RT-PCR. Relative COX-2 and MMP-1 levels were calculated by normalizing the band densities
to that of GAPDH and setting the zero controls as 100%. (A) Cells were treated with 30 nM trypsin for different time periods. COX-2 and GAPDH
proteins were assayed by western blotting. (B) After trypsin treatment for 8 hours, COX-2, MMP-1 and GAPDH mRNAs in the cells were analyzed
by RT-PCR and agarose gel electrophoresis, and then quantified. (C) After trypsin treatment for 8 hours, COX-2, MMP-1 and GAPDH protein levels
in the cells were analyzed and quantified.
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PAR2-AP, further enhanced the COX-2 level (Figure 3B).
These results indicate that PAR-2 activation by PAR2-AP
and trypsin leads to COX-2 expression, and PAR2-AP and
trypsin had additive effects on this reaction. To our
surprise, COX-2 may be more important than MMP-1 in
PAR-2-mediated responses in synovial cells.
The PAR2-IP inhibited trypsin-induced COX-2 expression
Effects of the PAR2-IP, SLAGKV, on COX-2 and MMP-1
expressions were also evaluated in SW982 synoviosarcoma
cells. When treated with the PAR2-IP, cell responses were
similar to those with the PAR-AP, but they seemed
reduced with PAR2-IP treatment (Figures 3A, 4A).
Since our experiments showed that trypsin induced
COX-2 expression (Figures 1, 2), and PAR2-AP pretreat-
ment further increased its level in cells (Figure 3), we
Figure 3 Induction of cyclooxidase-2 (COX-2) and matrix
metalloproteinase-1 (MMP-1)expression by proteinase-activated
receptor-2-activating peptide (PAR2-AP) in human
synoviosarcoma cells. Human synoviosarcoma SW982 cells were
starved in serum-free L15 medium and treated with the PAR2-AP, IL-
1b, and/or trypsin. Expressions of COX-2 and MMP-1 were analyzed by
western blotting, and relative levels were calculated by normalizing
the band densities to that of GAPDH and setting the zero controls as
100%. (A) Cells were treated with IL-1b at 5 ng/ml or PAR-2 AP at
different concentrations for 24 hours after 12 hours of starvation. (B)
Cells were pretreated with PAR2-AP at different concentrations for 30
minutes and then incubated with trypsin at 30 nM for 6 hours.
Figure 4 Inhibition of trypsin-induced cyclooxidase-2 (COX-2)
expression by proteinase-activated receptor-2-inhibiting
peptide (PAR2-IP) in human synoviosarcoma cells. Human
synoviosarcoma SW982 cells were treated with the PAR2-IP, IL-1b,
and/or trypsin in serum-free L15 medium. Expressions of COX-2 and
MMP-1 were analyzed by western blotting, and relative levels were
calculated by normalizing the band densities to that of GAPDH and
setting the zero controls as 100%. (A) Cells were treated with IL-1b
at 5 ng/ml or PAR-2 AP at different concentrations for 24 hours. (B)
Cells were pretreated with PAR2-AP at different concentrations for
30 minutes and then incubated with trypsin at 30 nM for 6 hours.
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induced COX-2 expression. It is plausible that the induc-
tion was reduced by the additional PAR2-IP in a dose-
dependent manner (Figure 4B). The result suggests that the
designated PAR2-IP inhibits trypsin-induced COX-2-
dependent inflammatory responses in synovial cells.
The PAR2-IP inhibited trypsin-induced NF-B activation
It was shown that activated PAR-2 is coupled to NF-B
activation in cells [13], and NF-B is involved in COX-2
transcriptional activation [14]. We then tested whether
the PAR2-IP interferes with NF-B activation. In control
experiments using primary and SW982 synovial cells,
treatment with 60 nM trypsin resulted in marked hos-
phorylation of p65, an activated form of NF-B, and
degradation of IBa, an inhibitor of NF-B (Figure 5A).
When cells were treated with PAR2-IP alone, phos-
phorylated p65 levels also increased, a phenomenon that
is consistent with the idea that PAR2-IP alone may
mimic PAR2-AP on PAR-2 signaling, as seen in Figure
4A. After pretreatment of cells with the PAR2-IP at 75
μM, the trypsin-induced phosphorylation of p65 was
inhibited in both cell types (Figure 5B). These results
suggest that the PAR2-IP inhibited trypsin-induced acti-
vation of NF-B, which regulates COX-2 expression and
inflammatory responses in human synovial cells.
Discussion
Previous studies showed that PAR2 activation results in
proinflammatory effects including vasodilatation, edema,
Figure 5 Inhibition of trypsin-induced nuclear factor (NF)-B activation by proteinase-activated receptor-2-inhibiting peptide (PAR2-IP)
in synovial cells. Human primary synovial cells or synoviosarcoma SW982 cells were treated with trypsin and/or PAR2-IP, and the levels of
phospho-p65 (p-p65), an activated NF-B, and/or IBa, an NF-B inhibitor, were analyzed by western blotting. (A) Cells were incubated in
serum-free DMEM medium (for primary cells) or L15 medium (for SW982 cells), and then treated with 60 nM trypsin for 15, 30, 60 and 120
minutes. (B) Cells were treated with 75 μM PAR2-IP or 60 nM trypsin alone for 30 minutes, or in combination with adding PAR2-IP first for 30
minutes and then trypsin for another 30 minutes. The relative levels of p-p65 were calculated by normalizing the band densities to that of
GAPDH and setting the controls as 100%.
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[5,28-31]. It was also suggested that luminal proteases
activate PAR-2 in the mouse colon to induce inflamma-
tion [31]. Following PAR-2 activation, the inflammatory
markers, COX-2 and MMP-1, were upregulated in
chondrocytes [4]. Our earlier study showed higher
expression levels of PAR-2 in human primary synovial
cells than in chondrocytes [12]. However, the role of
PAR-2 in synovial cells has not been well investigated.
Therefore in the present study, we investigated the
effects of PAR-2 activation and inhibition of COX-2 and
MMP-1 expressions in primary OA synovial cells as well
as in model cells, which suggested anti-inflammatory
mechanisms of the PAR2-IP.
Trypsin is well recognized as an activator of PAR2.
Importantly, trypsin was able to mimic carrageenan/kaolin
(C/K)-induced joint swelling, an effect that was abrogated
by inhibitors of this proteolytic enzyme [32]. Although
there could be a concern of trypsin-induced cell death,
similar conditions were used in other studies [13,33]. no
sign of increased protein degradation in cells treated with
trypsin, and the level of the marker protein, GAPDH, was
consistent after trypsin treatment in our experiments. Our
study demonstrated that the trypsin-PAR-2 interaction
induced COX-2 and MMP-1 expressions in both OA
chondrocytes and synovial cells; however, the effect on
COX-2 was more obvious than MMP-1 in synovial cells
(Figure 1). In primary synovial cells, trypsin induced both
COX-2 and MMP-1 protein productions; however, trypsin
tended to induce more COX-2 than MMP-1. Likewise this
phenomenon was also seen in PAR2-AP-induced COX-2
and MMP-1 expressions (Figure 3). These results suggest
that regulation of PAR-2 activity may differ between syno-
vial cells and chondrocytes.
To design the inhibiting peptide, PAR2-IP, we change
the isoleucine residue in the PAR2-AP to alanine, generat-
ing the SLAGKV peptide. With one residue modification,
this peptide has similar effects on PAR-2 signaling; how-
ever, it inhibited trypsin-induced COX-2 expression in a
dose-dependent manner (Figure 4B). The effect of trypsin
was entirely eliminated by PAR2-IP at a moderate concen-
tration (50 μM), suggesting a specific interaction between
PAR2-IP and trypsin. Similar phenomena were also seen
in trypsin-induced NF-B activation (Figure 5B). It is
known that the sequence of PAR2-AP is identical to tryp-
sin-digested N-terminal PAR-2, and they bind to the same
region of PAR2 [10,34]. In other words, PAR2-AP is able
to bind trypsin, however, without interference on its activ-
ity. Indeed, PAR2-AP and trypsin had additive effects to
promote COX-2 expression in the cells (Figure 3B). In the
contrary, PAR2-IP may bind to trypsin with high affinity,
and consequently inhibits its digesting activity.
Recent studies have demonstrated that trypsin- and
PAR2-AP-activated PAR-2 induces inflammatory
responses through p65 NF-B pathway in many cell
types. Electrophoretic mobility shift assays, reporter
gene assays, and morphological ransduction studies
revealed PAR-2-induced activation and translocation of
NF-B in human keratinocytes [13,35]. PAR-2 agonists
also activated p65-NF-B in endothelial and epithelial
cells [36,37]. Similarly we found that trypsin activated
NF-B in human synovial cells (Figure 5A). Furthermore
our data demonstrated inhibitory effect of PAR2-IP on
trypsin-induced activation of NF-B, and down-regula-
tion of inflammatory COX-2 expression in human syno-
viosarcoma and primary OA synovial cells.
It was shown that activation of PAR-2 results in
proinflammatory reactions via the production of cyto-
kines, such as IL-6, IL-8, and prostaglandin [38,39]. It
was also reported that PAR-2 activation induces produc-
tion of IL-1b and Inter-Cellular Adhesion Molecule
(ICAM)-1 by lung epithelial and umbilical vein endothe-
lial cells [40]. Those reports suggested that PAR-2 acti-
vation may be associated with local increases in serine
proteases that induce cytokine-related inflammation.
Although further studies may be required to discover
detailed mechanisms, application of PAR2-IP is sug-
gested as a potential therapeutic strategy for OA.
Conclusions
Our findings suggest that this PAR2-IP inhibits trypsin-
induced PAR-2 activation, and represses NF-B activity,
r e s u l t i n gi nar e d u c t i o ni ni n f l a m m a t o r yC O X - 2l e v e l s
in synovial cells. This is a novel finding that a PAR2-IP
can repress NF-B activation and COX-2 expression.
Herein we demonstrated a potential application of a
PAR-2 inhibitory strategy that may slow down the OA
disease progression and reduce patient symptoms.
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